Novel Insights into PARK7 (DJ-1), a Potential Anti-Cancer Therapeutic Target, and Implications for Cancer Progression
- PMID: 32357493
- PMCID: PMC7288009
- DOI: 10.3390/jcm9051256
Novel Insights into PARK7 (DJ-1), a Potential Anti-Cancer Therapeutic Target, and Implications for Cancer Progression
Abstract
The expression of PARK7 is upregulated in various types of cancer, suggesting its potential role as a critical regulator of the pathogenesis of cancer and in the treatment of cancer and neurodegenerative diseases, including Parkinson's disease, Alzheimer's disease, and Huntington disease. PARK7 activates various intracellular signaling pathways that have been implicated in the induction of tumor progression, which subsequently enhances tumor initiation, continued proliferation, metastasis, recurrence, and resistance to chemotherapy. Additionally, secreted PARK7 has been identified as a high-risk factor for the pathogenesis and survival of various cancers. This review summarizes the current understanding of the correlation between the expression of PARK7 and tumor progression.
Keywords: PARK7 (DJ-1); apoptosis; chemoresistance; redox sensor; therapeutic target.
Conflict of interest statement
The author declares no conflict of interests.
Figures


References
-
- Neumann M., Muller V., Gorner K., Kretzschmar H.A., Haass C., Kahle P.J. Pathological properties of the Parkinson’s disease-associated protein DJ-1 in alpha-synucleinopathies and tauopathies: Relevance for multiple system atrophy and Pick’s disease. Acta Neuropathol. 2004;107:489–496. doi: 10.1007/s00401-004-0834-2. - DOI - PubMed
-
- Wagenfeld A., Yeung C.H., Shivaji S., Sundareswaran V.R., Ariga H., Cooper T.G. Expression and cellular localization of contraception-associated protein. J. Androl. 2000;21:954–963. - PubMed